Formulation strategies for pulmonary delivery of poorly soluble drugs

Pulmonary Drug Delivery: Advances and Challenges

Volumn , Issue , 2015, Pages 87-121

  Wauthoz, Nathalie ^a   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

active pharmaceutical ingredients; co solvents; cyclodextrins; lungs; nanocrystal suspension; powder inhalation; pulmonary delivery; systemic pharmacokinetics; water soluble drugs

Indexed keywords

EID: 84977652379     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118799536.ch5     Document Type: Chapter

References (136)

1. Williams, H.D., Trevaskis, N.L., Charman, S.A., et al. (2013). Strategies to address low drug solubility in discovery and development. Pharmacological Reviews, 65(1), 315-499.
2. Shi, Y., Porter,W., Merdan, T. and Li, L.C. (2009). Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opinion on Drug Delivery, 6(12), 1261-1282.
3. vanHoogevest, P., Liu, X. and Fahr, A. (2011). Drug delivery strategies for poorlywater-soluble drugs: the industrial perspective. Expert Opinion on Drug Delivery, 8(11), 1481-1500.
4. Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413-420.
5. Labiris, N.R. and Dolovich, M.B. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology, 56(6), 588-599.
6. Jain, K.K. (2008). Drug delivery systems - An overview. Methods of Molecular Biology, 437, 1-50.
7. Patton, J.S., Fishburn, C.S. and Weers, J.G. (2004). The lungs as a portal of entry for systemic drug delivery. Proceedings of the American Thoracic Society, 1(4), 338-344.
8. Pilcer, G. and Amighi, K. (2010). Formulation strategy and use of excipients in pulmonary drug delivery. International Journal of Pharmaceutics, 392(1-2), 1-19.
9. Pilcer, G., Wauthoz, N. and Amighi, K. (2012). Lactose characteristics and the generation of the aerosol. Advanced Drug Delivery Reviews, 64(3), 233-256.
10. Son, Y.-J., Mitchell, J.P. and McConville, J.T. (2011). In vitro performance testing for pulmonary drug delivery, in Controlled Pulmonary Drug Delivery, (eds. H.D.C. Smyth and A.J. Hickey), Springer, New York, pp. 383-415.
11. Noyes, A.A. and Whitney, W.R. (1897). The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society, 19, 930-934.
12. Einstein, A. (1905). Über die von der molekularkinetischen Theorie der Wärme geforderte Bewegung von in runhenden Flüssigkeiten suspendierten Teilchen. Annall Physics, 17, 549.
13. Kirch, J., Guenther, M., Doshi, N., et al. (2012). Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge - an ex vivo and in silico approach. Journal of Controlled Release, 159(1), 128-134.
14. Fischer, H. andWiddicombe, J.H. (2006). Mechanisms of acid and base secretion by the airway epithelium. The Journal of Membrane Biology, 211(3), 139-150.
15. Ng, A.W., Bidani, A. and Heming, T.A. (2004). Innate host defense of the lung: effects of lung-lining fluid pH. Lung, 182(5), 297-317.
16. Patton, J.S. (1996). Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery Reviews, 19, 3-36.
17. West, J.B. (2012). Pulmonary Pathophysiology: The Essentials, Wolters Kluwer Health:Philadelphia.
18. Lippmann, M. and Schlesinger, R.B. (1984). Interspecies comparisons of particle deposition and mucociliary clearance in tracheobronchial airways. Journal of Toxicology and Environmental Health, 13(2-3), 441-469.
19. Munkholm, M. and Mortensen, J. (2013). Mucociliary clearance: pathophysiological aspects. Clinical Physiology and Functional Imaging, 34, 171-177
20. Stone, K.C., Mercer, R.R., Gehr, P., et al. (1992). Allometric relationships of cell numbers and size in the mammalian lung. American Journal of Respiratory Cell and Molecular Biology, 6(2), 235-243.
21. Ahsan, F., Rivas, I.P., Khan, M.A. and Torres Suarez, A.I. (2002). Targeting to macrophages:role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. Journal of Controlled Release, 79(1-3), 29-40.
22. Forbes, B., Asgharian, B., Dailey, L.A., et al. (2011). Challenges in inhaled product development and opportunities for open innovation. Advanced Drug Delivery Reviews, 63(1-2), 69-87.
23. Doan, T.V., Gregoire, N., Lamarche, I., et al. (2013). A preclinical PK modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin. European Journal of Pharmaceutical Sciences, 48(1-2), 223-230.
24. Clinicaltrials.gov. (2014, January 9). Available from: http://www.clinicaltrials.gov.
25. Bates, D.W., Su, L., Yu, D.T., et al. (2001). Mortality and costs of acute renal failure associated with amphotericin B therapy. Clinical Infectious Diseases, 32(5), 686-693.
26. Andes, D., Pascual,A. and Marchetti, O. (2009). Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrobial Agents and Chemotherapy, 53(1), 24-34.
27. Lass-Florl, C. (2011). Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs, 71(18), 2405-2419.
28. Denning, D.W., Lee, J.Y., Hostetler, J.S., et al. (1994). NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. The American Journal of Medicine, 97(2), 135-144.
29. Koshkina, N.V., Waldrep, J.C., Roberts, L.E., et al. (2001). Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clinical Cancer Research, 7(10), 3258-3262.
30. Videira, M.,Almeida,A.J. and Fabra, A. (2012). Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine: Nanotechnology, Biology, and Medicine, 8(7), 1208-1215.
31. Gagnadoux, F., Hureaux, J., Vecellio, L., et al. (2008). Aerosolized chemotherapy. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 21(1), 61-70.
32. Fulzele, S.V., Chatterjee, A., Shaik, M.S., et al. (2006). Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharmaceutical Research, 23(9), 2094-2106.
33. Zhang, J., Lv, H., Jiang, K. and Gao, Y. (2011). Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. International Journal of Pharmaceutics, 420(1), 180-188.
34. Tolman, J.A. and Williams, R.O., 3rd., (2010). Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Development and Industrial Pharmacy, 36(1), 1-30.
35. Sahib, M.N., Abdulameer, S.A., Darwis, Y., et al. (2012). Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations. Drug Design, Ddevelopment and Therapy, 6, 29-42.
36. Saari, M., Vidgren, M.T., Koskinen, M.O., et al. (1999). Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. International Journal of Pharmaceutics, 181(1), 1-9.
37. Cabral-Marques, H. and Almeida, R. (2009). Optimisation of spray-drying process variables for dry powder inhalation (DPI) formulations of corticosteroid/cyclodextrin inclusion complexes. European Journal of Pharmaceutics and Biopharmaceutics, 73(1), 121-129.
38. El-Gendy, N., Gorman, E.M., Munson, E.J. and Berkland, C. (2009). Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. Journal of Pharmaceutical Sciences, 98(8), 2731-2746.
39. Sahib, M.N., Darwis, Y., Peh, K.K., et al. (2011). Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations. International Journal of Nanomedicine, 6, 2351-2366.
40. Mezzena, M., Scalia, S., Young, P.M. and Traini, D. (2009). Solid lipid budesonide microparticles for controlled release inhalation therapy. The AAPS Journal, 11(4), 771-778.
41. Joshi, M.R. and Misra, A. (2001). Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech, 2(4), 25.
42. Patlolla, R.R., Chougule, M., Patel, A.R., et al. (2010). Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. Journal of Controlled Release, 144(2), 233-241.
43. Fahr, A., van Hoogevest, P., May, S., et al. (2005). Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. European Journal of Pharmaceutical Sciences, 26(3-4), 251-265.
44. Niven, R.W. (2011). Toward managing chronic rejection after lung transplant: the fate and effects of inhaled cyclosporine in a complex environment. Advanced Drug Delivery Reviews, 63(1-2), 88-109.
45. Taljanski, W., Pierzynowski, S.G., Lundin, P.D., et al. (1997). Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. Drug Metabolism and Disposition, 25(8), 917-920.
46. Zijlstra, G.S., Rijkeboer, M., Jan van Drooge, D., et al. (2007). Characterization of a cyclosporine solid dispersion for inhalation. The AAPS Journal, 9(2), E190-199.
47. Tam, J.M., McConville, J.T., Williams, R.O., 3rd, and Johnston, K.P. (2008). Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. Journal of Pharmaceutical Sciences, 97(11), 4915-4933.
48. Yamasaki, K., Kwok, P.C., Fukushige, K., et al. (2011). Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. International Journal of Pharmaceutics, 420(1), 34-42.
49. El-Gendy, N., Pornputtapitak, W. and Berkland, C. (2011). Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. European Journal of Pharmaceutical Sciences, 44(4), 522-533.
50. Pardeike, J.,Weber, S., Haber, T., et al. (2011). Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. International Journal of Pharmaceutics, 419(1-2), 329-338.
51. Yang, W., Johnston, K.P. and Williams, R.O., 3rd., (2010). Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. European Journal of Pharmaceutics and Biopharmaceutics, 75(1), 33-41.
52. Rundfeldt, C., Steckel, H., Scherliess, H., et al. (2013). Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. European Journal of Pharmaceutics and Biopharmaceutics, 83(1), 44-53.
53. Duret, C., Wauthoz, N., Sebti, T., et al. (2012). New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. International Journal of Nanomedicine, 7, 5475-5489.
54. Yang,W., Tam, J., Miller, D.A., et al. (2008). High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. International Journal of Pharmaceutics, 361(1-2), 177-188.
55. Duret, C., Merlos, R.,Wauthoz, N., et al. (2014). Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. European Journal of Pharmaceutics and Biopharmaceutics. 86(1), 46-64.
56. Duret, C.,Wauthoz, N., Sebti, T., et al. (2012). New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis. Pharmaceutical Research, 29(10), 2845-2859.
57. Duret, C., Wauthoz, N., Sebti, T., et al. (2012). Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. International Journal of Pharmaceutics, 428(1-2), 103-113.
58. Yang, W., Chow, K.T., Lang, B., et al. (2010). In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. European Journal of Pharmaceutical Sciences, 39(5), 336-347.
59. Moazeni, E., Gilani, K., Najafabadi, A.R., et al. (2012). Preparation and evaluation of inhalable itraconazole chitosan based polymeric micelles. Daru, 20(1), 85.
60. Surapaneni, M.S., Das, S.K. and Das, N.G. (2012). Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacology, 2012, 623139.
61. Gill, K.K., Nazzal, S. and Kaddoumi, A. (2011). Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 79(2), 276-284.
62. El-Gendy, N. and Berkland, C. (2009). Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharmaceutical Research, 26(7), 1752-1763.
63. Hureaux, J., Lagarce, F., Gagnadoux, F., et al. (2009). Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics, 73(2), 239-246.
64. Sinswat, P., Overhoff, K.A., McConville, J.T., et al. (2008). Nebulization of nanoparticulate amorphous or crystalline tacrolimus - single-dose pharmacokinetics study in mice. European Journal of Pharmaceutics and Biopharmaceutics, 69(3), 1057-1066.
65. Beinborn, N.A., Du, J., Wiederhold, N.P., et al. (2012). Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. European Journal of Pharmaceutics and Biopharmaceutics, 81(3), 600-608.
66. Tolman, J.A., Nelson, N.A., Son, Y.J., et al. (2009). Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. European Journal of Pharmaceutics and Biopharmaceutics, 72(1), 199-205.
67. FDA. (2014, January 9). Available from: http://www.accessdata.fda.gov/scripts/cder/IIG/.
68. Lewis, D.A., Young, P.M., Buttini, F., et al. (2013). Towards the bioequivalence of pressurized metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. European Journal of Pharmaceutics and Biopharmaceutics. 86, 31-37.
69. Trivedi, J.S. and Wells, M.L. (2000). Solubilization using Cosolvent Approach, in Water-Insoluble Drug Formulation, (ed. R. Liu), Interpharm Press, Denver, pp. 141-168.
70. Wu, C.Y. and Benet, L.Z. (2005). Predicting drug disposition via application of BCS: transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research, 22(1), 11-23.
71. Corcoran, T.E. (2006). Inhaled delivery of aerosolized cyclosporine. Advanced Drug Delivery Reviews, 58(9-10), 1119-1127.
72. Trammer, B., Amann, A., Haltner-Ukomadu, E., et al. (2008). Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo. European Journal of Pharmaceutics and Biopharmaceutics, 70(3), 758-764.
73. Burkart, G.J., Smaldone, G.C., Eldon, M.A., et al. (2003). Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharmaceutical Research, 20(2), 252-256.
74. Brewster, M.E. and Loftsson, T. (2007). Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews, 59(7), 645-666.
75. Stella, V.J. and He, Q. (2008). Cyclodextrins. Toxicologic Pathology, 36(1), 30-42.
76. Matilainen, L., Toropainen, T., Vihola, H., et al. (2008). In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. Journal of Controlled Release, 126(1), 10-16.
77. Marques, H.M.C., Hadgraft, J., Kellaway, I.W. and Taylor, G. (1991). Studies of cyclodextrin inclusion complexes. III. The pulmonary absorption of β-, DM-β- and HP-β-cyclodextrins in rabbits. International Journal of Pharmaceutics, 77, 297-302.
78. Salem, L.B., Bosquillon, C., Dailey, L.A., et al. (2009). Sparing methylation of betacyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. Journal of Controlled Release, 136(2), 110-116.
79. Mathia, N.R., Timoszyk, J., Stetsko, P.I., et al. (2002). Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. Journal of Drug Targeting, 10(1), 31-40.
80. Piel, G., Piette, M., Barillaro, V., et al. (2007). Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes. International Journal of Pharmaceutics, 338 (1-2), 35-42.
81. Evrard, B., Bertholet, P., Gueders, M., et al. (2004). Cyclodextrins as a potential carrier in drug nebulization. Journal of Controlled Release, 96(3), 403-410.
82. Fishburn, C.S. (2008). The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. Journal of Pharmaceutical Sciences, 97(10), 4167-4183.
83. Pasut, G. and Veronese, F.M. (2009). PEG conjugates in clinical development or use as anticancer agents: an overview. Advanced Drug Delivery Reviews, 61(13), 1177-1188.
84. Caliceti, P. and Veronese, F.M. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews, 55(10), 1261-1277.
85. Sheth, P. and Myrdal, P.B. (2011). Excipients utilized for modifying pulmonary drug release, in Controlled Pulmonary Drug Delivery, (eds. H.D.C. Smyth and A.J. Hickey), Springer, New York, pp. 237-263.
86. Youn, Y.S., Kwon, M.J., Na, D.H., et al. (2008). Improved intrapulmonary delivery of sitespecific PEGylated salmon calcitonin: optimization by PEG size selection. Journal of Controlled Release, 125(1), 68-75.
87. Wattendorf, U. and Merkle, H.P. (2008). PEGylation as a tool for the biomedical engineering of surface modified microparticles. Journal of Pharmaceutical Sciences, 97(11), 4655-4669.
88. Amoozgar, Z. and Yeo, Y. (2012). Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 4(2), 219-233.
89. Suk, J.S., Lai, S.K.,Wang, Y.Y., et al. (2009). The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials, 30(13), 2591-2597.
90. Klonne, D.R., Dodd, D.E., Losco, P.E., et al. (1989). Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. Drug and Chemical Toxicology, 12(1), 39-48.
91. Junghanns, J.U. and Muller, R.H. (2008). Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicine, 3(3), 295-309.
92. O’Riordan, T.G. (2002). Formulations and nebulizer performance. Respiratory Care, 47(11), 1305-1312; discussion 1312-1303.
93. Weber, S., Zimmer, A. and Pardeike, J. (2013). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 86, 7-22.
94. Groneberg, D.A.,Witt, C.,Wagner, U., et al. (2003). Fundamentals of pulmonary drug delivery. Respiratory Medicine, 97(4), 382-387.
95. Sekiguchi, K. and Obi, N. (1961). Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chemical and Pharmaceutical Bulletin, 9(11), 866-872.
96. Vasconcelos, T., Sarmento, B. and Costa, P. (2007). Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today, 12(23-24), 1068-1075.
97. Chiou,W.L. and Riegelman, S. (1971). Pharmaceutical applications of solid dispersion systems. Journal of Pharmaceutical Sciences, 60(9), 1281-1302.
98. Janssens, S. and Van den Mooter, G. (2009). Review: physical chemistry of solid dispersions. The Journal of Pharmacy and Pharmacology, 61(12), 1571-1586.
99. Nanda, A.R., Rowling, C.E., Barker, N.P. and Sheen, P.-C. (2000). Immediate release solid dispersions for oral drug delivery, in Water-Insoluble Drug Formulation, (ed. R. Liu), Interpharm Press, Denver, pp. 493-523.
100. Freiwald, M., Valotis, A., Kirschbaum, A., et al. (2005). Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respiratory Research, 6, 21.
101. Torchilin, V.P. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical Research, 24(1), 1-16.
102. Liu, R., Sadrzadeh, N. and Constantinides, P.P. (2000). Micellization and drug solubility enhancement, in Water-insoluble Drug Formulation, (ed. R. Liu), Interpharm Press: Denver, pp. 213-354.
103. Soo, P.L., Liu, J., Allen, C., et al. (2006). Polymeric micelles for formulation of anticancer drugs, in Nanotechnology for Cancer Therapy, (ed. M.M. Amiji), Floride, pp. 317-355.
104. Owen, S.C., Chan, D.P.Y. and Shoichet, M.S. (2012). Polymeric micelle stability. Nano Today, 7(1), 53-65.
105. Kedar, U., Phutane, P., Shidhaye, S. and Kadam, V. (2010). Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine: Nanotechnology, Biology, and Medicine, 6(6), 714-729.
106. Lukyanov, A.N. and Torchilin, V.P. (2004). Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Advanced Drug Delivery Reviews, 56(9), 1273-1289.
107. Granata, F., Nardicchi, V., Loffredo, S., et al. (2009). Secreted phospholipases A(2): A proinflammatory connection between macrophages and mast cells in the human lung. Immunobiology, 214(9-10), 811-821.
108. Smola, M., Vandamme, T. and Sokolowski, A. (2008). Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. International Journal of Nanomedicine, 3(1), 1-19.
109. Selvam, S. and Mishra,A.K. (2008). Disaggregation of amphotericin B by sodium deoxycholate micellar aggregates. Journal of Photochemistry and Photobiology. B: Biology, 93(2), 66-70.
110. Jain, J.P. and Kumar, N. (2010). Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: factors affecting size and in vitro evaluation. European Journal of Pharmaceutical Sciences, 40(5), 456-465.
111. Ruijgrok, E.J., Fens, M.H., Bakker-Woudenberg, I.A., et al. (2005). Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. The Journal of Pharmacy and Pharmacology, 57(10), 1289-1295.
112. Koizumi, T., Kubo, K., Kaneki, T., et al. (1998). Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrobial Agents and Chemotherapy, 42(7), 1597-1600.
113. Niki, Y., Bernard, E.M., Schmitt, H.J., et al. (1990). Pharmacokinetics of aerosol amphotericin B in rats. Antimicrobial Agents and Chemotherapy, 34(1), 29-32.
114. Lowry, C.M., Marty, F.M., Vargas, S.O., et al. (2007). Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transplant Infectious Disease: An Official Journal of the Transplantation Society, 9(2), 121-125.
115. Ruijgrok, E.J., Vulto, A.G. and Van Etten, E.W. (2001). Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. The Journal of Antimicrobial Chemotherapy, 48(1), 89-95.
116. Burgess, B.L., Cavigiolio, G., Fannucchi, M.V., et al. (2010). A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties. International Journal of Pharmaceutics, 399(1-2), 148-155.
117. Sakagami, M., Kinoshita, W., Sakon, K., et al. (2002). Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. Journal of Controlled Release, 80(1-3), 207-218.
118. Oberdorster, G. (2001). Pulmonary effects of inhaled ultrafine particles. International Archives of Occupational and Environmental Health, 74(1), 1-8.
119. Pepic, I., Lovric, J. and Filipovic-Grcic, J. (2013). How do polymeric micelles cross epithelial barriers? European Journal of Pharmaceutical Sciences, 50(1), 42-55.
120. Swaminathan, J. and Ehrhardt, C. (2011). Liposomes for pulmonary drug delivery, In Controlled Pulmonary Drug Delivery, (eds. H.D.C. Smyth and A.J. Hickey), Springer, New York, pp. 313-334.
121. Cipolla, D., Gonda, I. and Chan, H.K. (2013). Liposomal formulations for inhalation. Therapeutic Delivery, 4(8), 1047-1072.
122. Kleemann, E., Schmehl, T., Gessler, T., et al. (2007). Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharmaceutical Research, 24(2), 277-287.
123. Griese,M., Schams, A. and Lohmeier, K.P. (1998). Amphotericin B and pulmonary surfactant. European Journal of Medical Research, 3(8), 383-386.
124. Ouyang, C., Choice, E., Holland, J., et al. (1995). Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange. Transplantation, 60(9), 999-1006.
125. Arppe, J., Vidgren, M. and Waldrep, J.C. (1998). Pulmonary pharmacokinetics of cyclosporin A liposomes. International Journal of Pharmaceutics, 161(2), 205-214.
126. Gilbert, B.E.,Knight, C., Alvarez, F.G., et al. (1997). Tolerance of volunteers to cyclosporineAdilauroylphosphatidylcholine liposome aerosol. American Journal of Respiratory and Critical Care Medicine, 156(6), 1789-1793.
127. Muller, R.H., Mader, K. and Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161-177.
128. Bunjes, H. (2010). Lipid nanoparticles for the delivery of poorly water-soluble drugs. The Journal of Pharmacy and Pharmacology, 62(11), 1637-1645.
129. Muller, R.H., Petersen, R.D., Hommoss, A. and Pardeike, J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Advanced Drug Delivery Reviews, 59(6), 522-530.
130. Mehnert, W. and Mader, K. (2001). Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews, 47(2-3), 165-196.
131. Souto, E.B. and Müller, R.H. (2010). Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes, in Drug Delivery, (ed.M. Schäfer-Korting), Springer, Berlin Heidelberg, pp. 115-141.
132. Müller, R.H. and Olbrich, C. (1999). Solid lipid nanoparticles: phagocytic uptake, in vitro cytotoxicity and in vivo biodegradation 1st communication. Pharm Ind, 61, 462-467.
133. Bocca, C., Caputo, O., Cavalli, R., et al. (1998). Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. International Journal of Pharmaceutics, 175, 185-193.
134. Nassimi, M., Schleh, C., Lauenstein, H.D., et al. (2010). A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. European Journal of Pharmaceutics and Biopharmaceutics, 75(2), 107-116.
135. Videira, M.A., Gano, L., Santos, C., et al. (2006). Lymphatic uptake of lipid nanoparticles following endotracheal administration. Journal of Microencapsulation, 23(8), 855-862.
136. BCS. (2014 January 9). Available from: http://166.78.14.201/tsrlinc.com/services/bcs/results.cfm.